China's bio-pharmaceutical industry explores companies to grow as the main forces for R&D

Business Club August 26th The combination of production, learning and research is an important part of the national technological innovation system. The discussion of its development model has risen to the height of the national innovation strategy. China's biopharmaceutical industry is still in its infancy, and it is particularly important to strengthen its exploration of the combination of production, education and research. This article analyzes the development characteristics, combination patterns, and development trends of production, education, and research in China's biomedical industry. The author believes that in the future, China's scientific research institutes still bear the important task of basic research, and service-oriented enterprises will become the main forces for research and development. For enterprises, only focusing on the application, focusing on the market, and carrying out targeted new drug research and development work can inject vitality and motivation into the development of the biopharmaceutical industry.

In the Chinese biopharmaceutical industry system, enterprises are the ultimate implementers of industrialization, and they are also direct players in market competition; while R&D institutions and institutions of higher learning have obvious advantages in scientific research, achievements, talents, and information, they are therefore The combination of innovative models will eventually become the most effective driving force for rapid industrial development and rapid economic growth. It can be seen that the innovation mode of production, education, and research is the synergy and integration of scientific research, education, and production in different social divisions of work in terms of function and resource advantages. It is the connection between the upper, middle, and lower reaches of the technological innovation system, and it is also an effective form and approach to optimize corporate science and technology behavior. .

Strain

For developing countries like China, the biopharmaceutical industry is still in its infancy. Relatively concentrated resources, weak corporate innovation, lack of innovation in products, excessive repeated investment, and vicious competition have always been the focus of the country's reforms, but reforms are not It may be necessary to proceed step by step. Therefore, the exploration of a combination of production, education and research to optimize the allocation of resources, reduce costs, increase efficiency, and enhance competitiveness are both the needs of the industry's development strategy and it is also necessary.

In the innovation system, the state always regards large-scale scientific research institutes and universities as an important force for technological innovation. Its investment and support efforts are also gradually increasing. As a result, these research institutes and universities are allocated resources, talent reserves, Information channels and other aspects enjoy unique conditions. This trend is particularly prominent in high-tech fields such as biomedicine.

The support of the country and years of accumulation have created these research institutes and universities to become the main force for the development of new drugs in China, and they still occupy a dominant position in the mode of production, education and research.

With the continuous refinement of the global innovation division of labor, the innovation chain has been lengthened in the field of new drug development. In order to achieve the optimal allocation of resources, the new drug R&D chain has been divided into multiple links. Small and medium-sized R&D service companies have gradually become this chain. The most active component. Because of its small organizational framework, full personnel and funding are fully concentrated, and after gaining technical support advantages in a certain aspect of new drug R&D, it can be used as a starting point to fully play its role in the chain of production, education, and research.

According to statistics, after several decades of reforms, the number of scientific research institutes in China has been greatly reduced, from more than 5,000 before the reform to more than 3,000, of which 1200 development institutes have been transformed into enterprises. These major measures have played a crucial role in the construction of the national innovation system. Many large-scale high-tech companies are currently undergoing transformation.

With the reforms in China for several decades, the diversification of Chinese pharmaceutical companies' investment entities and the rapid development of medical science and technology have laid a good foundation for the rapid development of China's biomedical industry. The current problem that needs to be solved is that due to factors such as the disorderly development of the previous period, a series of unfavorable factors, such as low conversion rate of results, unreasonable resource structure, and unscientific product structure, have seriously hindered the development of the integrated production, education, and research system of biomedicine. Compared with developing countries such as India, there is a big gap from the mechanism to the operation.

Various modes

Regional industrial alliances. Relying on the support of local governments, the integration of scientific research institutes and university resources in the region with the establishment of regional industrial alliances with local biopharmaceutical companies is a common pattern of production, education and research in all regions of China. Such as the Nanjing Biopharmaceutical Industry Alliance and Xi'an Biopharmaceutical Industry R&D Alliance.

Regional service alliances. Relying on local scientific and technological resources, establishing a regional service alliance is a major practice in large-scale cities in China. Typical examples include Beijing Zhongguancun R&D Outsourcing Alliance, Beijing Biotechnology Outsourcing Alliance, Capital Science and Technology Conditional Platform, and Shanghai Science and Technology Conditional Platform.

Industry alliances divided by profession. It is also the main practice of the domestic biopharmaceutical industry that enterprise-led, combined with professional research institutes and universities to establish a professional mode of production, research and research system. The typical Shiyou Pharmaceutical Group took the lead in 27 antibiotics, vitamins, and scientific research institutes and institutions, established a strategic alliance for technological innovation in the antibiotics and vitamins industry, and recently established a strategic alliance for influenza vaccine technology innovation led by the Zhongsheng Group.

The future can be treated

Most of the research institutes in the field of biomedicine in China have a background of government support, and generally have a profound scientific research culture. Although it is still at the forefront of the national biopharmaceutical industry R&D and innovation system at this stage, with the further exchange of talents, further intensified market competition, and further improvement of the enterprise innovation system, scientific research institutes will gradually take a role in the production, research and development system. . As the main body of innovation, enterprises have already demonstrated advantages in many domestic industries. Only by focusing on the application and focusing on the market, can we develop targeted drug research and development to inject vitality and motivation into the development of the biopharmaceutical industry.

In the national 12th Five-Year Plan's demonstration work, in the national biopharmaceutical industry innovation support system represented by the “National New Drug Creation Major Project”, the tendency of reliance on the tendency of enterprises to create innovation platforms has become increasingly prominent. It is the future of scientific research institutes. The role change in the industry-university-research system provides an important basis. In the mode of production, learning, and research where companies are the mainstay of innovation, scientific research institutes will use their advantages in different disciplines and may gradually develop into an important role in undertaking basic research, key technology research, and personnel training. Fundamental research is the source of the entire new drug research and development. Key technologies are important elements for enhancing industrial productivity. Talent resources are the executors of the industry-university-research system. Therefore, scientific research institutes have a strong role in the production, research and research system.

In the research of the industry-university-research-and-research system, many experts have proposed the concept of "officials" and "investments" to innovatively propose "government, production, learning, research, and funding." Among them, the “government” represents the government’s support, and the “investment” represents the introduction of capital operations. These two elements provide very beneficial supplementary roles for the development model of production, education, and research. From the advanced cases abroad, we can find that government support is the key factor that determines the success of the industry-university-research model, and the introduction of the concept of capital accelerates the development of new drugs and industrialization, as well as financial support.

The combination of production, education, and research in China's science and technology innovation system has risen to the height of national strategy. From funding support to the formulation of the "Science and Technology Progress Law," innovation models for production, learning, and research have been initiated at all levels. Taking the Beijing Science and Technology Commission as an example, the establishment of a corporate innovation base and the establishment of a capital conditional platform have all demonstrated support and assistance for the development of production, education and research. In capital intervention, venture capital, various types of funds, and even the upcoming GEM will create a healthy external environment for the development of production, education and research in the field of biomedicine in China.